Sanofi Immune Drug Hopeful Posts Mixed Results in Mid-Stage Tests

Why It Matters

The outcomes will shape whether lunsekig can replace Dupixent as Sanofi's flagship biologic and protect revenue as patents expire, while the asthma success suggests broader respiratory potential despite the eczema miss.

Key Takeaways

• Lunsekig met endpoints in asthma and nasal polyps trials
• Eczema trial failed to achieve primary skin clearance goal
• Drug targets TSLP and IL‑13, aiming for broader immunologic impact
• Phase 3 COPD studies ongoing, expanding respiratory pipeline
• Analysts project up to $3 billion peak annual sales

Pulse Analysis

Sanofi’s bispecific antibody lunsekig arrives at a pivotal moment for the company’s immunology franchise. Dupixent, co‑developed with Regeneron, accounts for roughly a third of Sanofi’s sales and faces patent cliffs after 2031. To sustain growth, Sanofi has invested heavily in next‑generation biologics that simultaneously inhibit thymic stromal lymphopoietin (TSLP) and interleukin‑13 (IL‑13), a strategy designed to broaden efficacy across multiple inflammatory pathways. The dual‑target approach reflects a broader industry trend toward multiplexed antibodies that can address heterogeneous disease phenotypes while differentiating from existing monotherapies.

The Phase 2 data present a nuanced picture. In moderate‑to‑severe asthma, lunsekig delivered statistically significant reductions in exacerbations and measurable gains in forced expiratory volume, outcomes that held regardless of baseline biomarker status. A parallel trial in chronic rhinitis with nasal polyps demonstrated meaningful reductions in polyp size and congestion, reinforcing the drug’s potential in upper‑airway disease. Safety signals remained comparable to placebo, with serious adverse events and discontinuations mirroring control arms. However, the atopic dermatitis study fell short of its primary skin‑clearance target, underscoring the difficulty of translating synergistic TSLP/IL‑13 inhibition into dermatologic benefit.

Looking ahead, Sanofi’s pipeline now leans on ongoing Phase 3 COPD trials to expand lunsekig’s respiratory footprint. Analysts such as Jefferies project peak annual sales of up to $3 billion based solely on lung‑focused indications, a valuation that could rise if the COPD data confirm efficacy. The mixed results also send a signal to investors: while the drug may not dethrone Dupixent in eczema, its respiratory performance could secure a new revenue pillar for Sanofi, helping offset upcoming patent expirations and reinforcing its position in the competitive biologics market.